Cybin Inc’s Post

Unlock the Future of Drug Screening with DefiniGEN's iPSC-Derived PFIC2 Cells!   Discover the game-changing advantages of our iPSC-derived PFIC2 cells in drug screening which overcome the common issues when screening with primary cells and mouse models:   Biological Relevance: Accurately mimic human disease phenotype. Consistency: No batch-to-batch variation since our cells are sourced from a single donor, giving you reproducible data. Scalability: We can scale to meet your extensive screening needs Our innovative technology addresses limitations of traditional models, paving the way for breakthroughs in PFIC2 therapeutics.   Learn more by reading our blog here: https://lnkd.in/eKspSV8F   #DrugDiscovery #iPSC #Pharma #Biotech #Innovation #DefiniGEN #PFIC

Did you miss our recent webinar on "Efficiently Driving Protein-based #NMR Fragment Screening and Lead Discovery" ? Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, explored the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. If you missed any part of it, no worries! You can catch the recorded session here: https://lnkd.in/d9RfpXfs #dataautomation #FragmentBasedDrugDiscovery #Mnova #Mestrelab

Gain critical information to address the unexpected. Learn how Johnson & Johnson used new workflows to quickly identify undesirable PTMS and enable improvements in process development. "We are increasingly seeing custom colors in new therapeutics being brought to market. Using the Intabio ZT system from SCIEX with an electron activated dissociation (EAD)-based MAM workflow we've been able to identify advanced glycation end products (AGEs) in the acidic proteoform that have been linked to color changes." Listen to the whole story here: https://buff.ly/3Wp6Qme #ContinuousImprovement #mAbDevelopment #Biotherapeutics

If like Alexis Moreno and Reece Gardner you're working on challenging targets like GPCRs and IDPs, join this upcoming webinar where they'll share how they successfully measured binding affinities with Spectral Shift!

𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗿𝗲𝗮𝗸 𝘆𝗲𝘁? Time is running out – this event is happening on Thursday! 📅 Date: May 16th, 2024 🕓 Time: 16:00 CEST Reserve your seat for an enlightening first session with Dr. Matthias Gossmann at the LabINAR BREAK, hosted by innoVitro. Discover the transformative strategies in drug discovery using iPSC-cellular models during the webinar “Transforming Drug Discovery: Accelerating Regulatory Acceptance by Integrating Throughput into Microphysiological Systems". What can you expect? ▪️ Case studies highlighting the successful application of these models ▪️ Insights on utilizing cell-based platforms for efficient preclinical drug screening ▪️ An engaging & interactive Q&A sessions with field experts. Will we see you at the webinar? Register today to reserve your spot. Secure your registration: https://ow.ly/JTE950RuB0I #InnovativeDrugDiscovery #Webinar #HighThroughput #iPSCModels #Preclinical #PharmaceuticalDevelopment

Were excited to announce that Neucin will be attending the London Biotechnology Show next week! The event takes place at Olympia West from the 8th - 9th of May, so if you are attending and would like to find out more about our medical device design and development expertise then why not grab a coffee ☕️ and have a chat with Neucin’s Gavin Kovacs and Henry Verity. The London Biotechnology Show promises to be a fantastic event and were looking forward to some great discussions and meetings, catching-up with some familiar faces and making new connections from across the biotech sector. ➡️ For more information about the London Biotechnology Show visit 👉 https://lnkd.in/edrr2ACP If you would like to find out more about Neucin and how we could support your medical device design and development, then we’d love to hear from you. Get in touch 👉 info@neucindesign.com   #medicaldevices #innovation #design #engineering #research #technology #medtech #researchanddevelopment #productdesign #productdevelopment #development #drugdelivery #nasal #pharma #pharmaceuticals #diagnostics #devices #healthtech #healthtechnology #innovationinhealthcare #respiratory #respiratorydrugdelivery #inhalation #inhaler #DPI #MDI #SMI #nebuliser #oindp #pharmaceuticals #formulation #respiratory #pulmonary #networkingopportunities #exhibitions #conferences #lbs #lbs24 #londonbiotechnologyshow #biotechnology #projects #acceleratedevelopment #neucin #neucininnovates

Propofol antibody – a world first 🌍 We have filed an application for our third patent family; an antibody to propofol. This is a fantastic milestone that many others have failed to achieve. Our efforts did not work at the first attempt but required the application of scientific research rigour whilst trialling different ways of rendering propofol immunogenic, that is, causing an antibody reaction. Having protected our intellectual property, we can now exploit it through immunoassay-based monitoring solutions. These are commonly used in a variety of near-patient drug assays and will form the basis of our first monitor; ProSedTM. As described in our Business Plan, our novel antibody also offers commercialisation opportunities in its own right. #healthcare #medtech #investornews

Throughout September, we’ve been singing the praises of our bespoke CellOPTIQ® platform – you’ll have to excuse us, but we’re rather proud of it!   That’s because our CellOPTIQ® platform enables testing of potential new medicines for heart failure therapeutics. It generates voltage, calcium and contractility data from hiPSC cardiomyocytes and adult cardiomyocytes, enabling the discovery of new drugs for heart conditions, whilst saving clients time and money, and ensuring unparalleled accuracy.   However, we’re not just boasting, we promise! We’ve been putting our evidence where our mouths are!   As well as the results of the validation experiments we shared earlier this month, take a look at this comparison of CellOPTIQ® with rabbit wedge and other modalities, using 19 reference compounds, below. As you can see, CellOPTIQ® outclasses many of the comparable platforms, especially in the identification of known reference compounds. In fact, CellOPTIQ® was the only platform without a false negative liability!   So, if you’re in the process of starting a study, or embarking on testing new drugs, perhaps we can help? Don’t hesitate to get in touch: we’d love to hear from you!   Mark Bryant Richard Henderson Godfrey Smith #clydebiosciences #pharma #research 

Iambic ups rhythm in AI-enabled race to clinic, revealing $100M round and Nvidia pact >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical

In today's competitive landscape, SENDIG v3.1.1 isn't just an option—it's essential. Discover its pivotal role in preclinical studies in our latest guide, How to Use SENDIG v3.1.1 for Improved Standardization of Drug Development. Learn how to use SENDIG v3.1.1 for improved standardization of drug development and how to optimize your SEND datasets. Access now. https://lnkd.in/d-HX6mF4